Clinical Trials

47 enrolled

Lung Neoplasms

NCT03706690 2026-05-13

PACIFIC-5

407 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT04550260 2026-05-13

KUNLUN

640 enrolled

Esophageal Squamous Cell Carcinoma

NCT06732401 2026-05-13

CLEAR

630 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02264678 2026-05-12

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

354 enrolled

Gynecologic

Ovarian Neoplasms

NCT02453282 2026-05-12

MYSTIC

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT03819465 2026-05-12

MAGELLAN

175 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07081633 2026-05-12

TREMENDOUS-2

114 enrolled

Carcinoma, Hepatocellular

NCT03459846 2026-05-11

BAYOU

154 enrolled 13 charts

Urinary Bladder Neoplasms

NCT03601455 2026-05-11

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

13 enrolled

Urinary Bladder Neoplasms

NCT04716946 2026-05-11

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

13 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05092412 2026-05-08

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

30 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04116047 2026-05-07

CompARE

785 enrolled

Head & Neck

Oropharyngeal Neoplasms

NCT05154994 2026-05-07

RESOLVE

9 enrolled

Carcinoma, Transitional Cell

NCT02484404 2026-05-06

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

268 enrolled

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT05170204 2026-05-06

HORIZON 1

68 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06094140 2026-05-06

NEO-IMPACT

20 enrolled

Pancreatic Neoplasms

NCT03482102 2026-05-04

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

37 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT03660826 2026-05-04

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

288 enrolled 21 charts

Sarcoma

Carcinosarcoma, Carcinoma, Endometrioid

NCT03775486 2026-05-01

ORION

401 enrolled 26 charts

Non-small Cell Lung Cancer NSCLC

NCT04092283 2026-05-01

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

660 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04999969 2026-04-30

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

126 enrolled 30 charts

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumours

NCT05883644 2026-04-30

SIERRA

111 enrolled

Liver Neoplasms

NCT03842228 2026-04-29

COD

39 enrolled 15 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT05063565 2026-04-29

ROWAN

100 enrolled

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT02143466 2026-04-24

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

344 enrolled

Advanced Non Small Cell Lung Cancer

NCT03742102 2026-04-24

BEGONIA

243 enrolled 13 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04745689 2026-04-24

TAZMAN

31 enrolled 15 charts

Small Cell Lung Carcinoma

NCT06045975 2026-04-24

DUMELEP

30 enrolled

Carcinoma, Hepatocellular

NCT03682289 2026-04-23

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

GastrointestinalGenitourinaryGynecologic

83 enrolled

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT03833154 2026-04-23

PACIFIC-4

724 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05617963 2026-04-23

DURVALUNG

100 enrolled

Small Cell Lung Carcinoma

NCT03043872 2026-04-22

CASPIAN

987 enrolled 42 charts 1 FDA

Small Cell Lung Carcinoma

NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

200 enrolled

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT05687266 2026-04-22

AVANZAR

1,350 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03837899 2026-04-21

Durvalumab and Tremelimumab for Pediatric Malignancies

Other hematologic neoplasm

50 enrolled 59 charts

Neoplasms, Hematologic Neoplasms

NCT05771480 2026-04-21

TOURMALINE

142 enrolled

Biliary Tract Neoplasms

NCT02516241 2026-04-20

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Urothelial Cancer

NCT02734004 2026-04-20

MEDIOLA